Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 2/3 1Phase 2 1

Status

Terminated 1Recruiting 1Enrolling by invitation 1Completed 1

Sponsor Class

OTHER 2INDUSTRY 2

Study Type

Interventional 4

Sponsor

Cancer Type

Head & Neck 6Genitourinary 5Other hematologic neoplasm 4Lymphoid 4Dermatologic 4CNS 4Thoracic 3Gastrointestinal 3Sarcoma 2Gynecologic 2Plasma cell 1Breast 1

Conditions

Hodgkin Disease 47Lymphoma 22Lymphoma, Non-Hodgkin 18Lymphoma, Large B-Cell, Diffuse 15Multiple Myeloma 12Melanoma 9Lymphoma, B-Cell 9Leukemia, Lymphocytic, Chronic, B-Cell 9Hematologic Neoplasms 9Lymphoma, Follicular 7Myelodysplastic Syndromes 5Mycosis Fungoides 5Lymphoma, T-Cell, Peripheral 5Lymphoma, T-Cell 5Lymphoma, Large-Cell, Anaplastic 5Carcinoma, Renal Cell 5Burkitt Lymphoma 5Uterine Cervical Neoplasms 4Recurrence 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Neoplasm Metastasis 4Lymphoma, T-Cell, Cutaneous 4Lymphoma, B-Cell, Marginal Zone 4Colorectal Neoplasms 4Carcinoma, Merkel Cell 4Breast Neoplasms 4Stomach Neoplasms 3Squamous Cell Carcinoma of Head and Neck 3Small Cell Lung Carcinoma 3Pancreatic Neoplasms 3

Interventions

Cyclophosphamide 100Rituximab 82fludarabine phosphate 46Peripheral Blood Stem Cell Transplantation 45fludarabine 43Lenalidomide 35Filgrastim 33Methotrexate 32Cytarabine 32Busulfan 32Etoposide 31venetoclax 30Cyclosporine 30Dexamethasone 29Radiotherapy 28Mycophenolic Acid 28Melphalan 28Bendamustine Hydrochloride 25Antilymphocyte Serum 25Vincristine 24Gemcitabine 24ibrutinib 22Whole-Body Irradiation 22Doxorubicin 20Tacrolimus 19Methylprednisolone 18Bortezomib 18Brentuximab Vedotin 16pembrolizumab 15Prednisone 15

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Recurrence × Nivolumab × Lymphoid × Clear all
NCT06931613 2025-04-17

Autologous Hematopoietic Stem Cell Transplantation in Pediatric Relapsed or Refractory Hodgkin Lymphoma After Nivolumab Treatment

St. Petersburg State Pavlov Medical University

Phase 2 Enrolling by invitation
20 enrolled
Lymphoid

Hodgkin Disease, Recurrence

NCT05595447 2025-03-12

Treatment Strategy for Relapsed/Refractory Hodgkin Lymphoma

Hospital Regional de Alta Especialidad del Bajio

Phase 2/3 Recruiting
20 enrolled
Lymphoid

Hodgkin Disease, Recurrence

NCT02061761 2023-03-24

A Study to Evaluate the Safety, Tolerability, and Efficacy of Relatlimab in Relapsed or Refractory B-Cell Malignancies

Bristol-Myers Squibb

Phase 1/2 Completed
106 enrolled 27 charts
LymphoidOther hematologic neoplasm

Hodgkin Disease, Lymphoma, Non-Hodgkin, Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell, Hematologic Neoplasms

NCT04730349 2023-03-24

PIVOT IO 020

Bristol-Myers Squibb

Phase 1/2 Terminated
15 enrolled 14 charts
CNSDermatologicLymphoidOther hematologic neoplasmSarcoma

Ependymoma, Glioma, Leukemia, Lymphoma, Lymphoma, Non-Hodgkin, Medulloblastoma, Melanoma, Neoplasms, Neuroblastoma, Recurrence, Rhabdomyosarcoma, Sarcoma, Ewing, Leukemia, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡